Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Uveal Melanoma × pembrolizumab × Clear all

Phase

Status

Sponsor Class

OTHER 6 INDUSTRY 4 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Ovarian Neoplasms 2 Melanoma 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcopenia 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Diseases 1 Neoplasms, Glandular and Epithelial 1 Gliosarcoma 1 Glioblastoma 1 Genital Neoplasms, Female 1 Endometrial Neoplasms 1 Efficacy, Team 1 Carcinoma, Ovarian Epithelial 1 Advanced Solid Tumours 1 Advanced Solid Tumor 1 Adrenocortical Carcinoma 1

Interventions

Melphalan 3 Interleukin-2 3 Nivolumab 2 Ipilimumab 2 pembrolizumab 1 entinostat 1 Tramadol 1 Ibuprofen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02697630 2023-12-08

PEMDAC

Vastra Gotaland Region

Phase 2 Completed

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡